Purpose

This is a prospective longitudinal cohort study to evaluate the impact of COVID-19 vaccination and booster on maternal and infant immunity against COVID-19 variants over time.

Condition

Eligibility

Eligible Ages
Between 13 Years and 55 Years
Eligible Genders
Female
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Singleton gestation - Received mRNA bivalent COVID-19 booster during 1) pregnancy or 2) breastfeeding

Exclusion Criteria

  • Multifetal gestation - Unable to provide consent

Study Design

Phase
Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Arm Groups

ArmDescriptionAssigned Intervention
COVID-19 booster in pregnancy Pregnant singletons who have received COVID-19 booster in pregnancy
  • Drug: Bivalent COVID-19 Booster
    Bivalent COVID-19 Booster by Pfizer or Moderna
COVID-19 booster in breastfeeding Breastfeeding individuals who have received COVID-19 booster while breastfeeding
  • Drug: Bivalent COVID-19 Booster
    Bivalent COVID-19 Booster by Pfizer or Moderna

Recruiting Locations

Thomas Jefferson University Hospital
Philadelphia, Pennsylvania 19107
Contact:
Rupsa C Boelig, MD
rupsa.boelig@jefferson.edu

More Details

NCT ID
NCT05543993
Status
Recruiting
Sponsor
Thomas Jefferson University

Study Contact

Brandy Firman
215-586-1656
brandy.firman@jefferson.edu

Detailed Description

We will enroll 100 pregnant patients who have received COVID-19 mRNA booster as well as 100 breastfeeding patients who have received COVID-19 mRNA booster. Participants will be following longitudinally through 3 months post partum, or 3 months post enrollment for those in the breastfeeding cohort. Maternal blood will be collected, as will cordblood at delivery, breastmilk, and infant samples.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.